Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S P Blatt

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
AIDS (London, England)|April 1, 1995
Rates of p24 antigenemia and viral isolation in comparable white and black HIV-infected subjects. Military Medical Consortium for Applied Retroviral ResearchA E Brown, J R Lane, K F Wagner, et al.
Clinical and Diagnostic Laboratory Immunology|July 1, 1995
Presence of neutralizing antibodies to heterologous human immunodeficiency virus type 1 isolates in sera of infected individuals is not predictive of rate of disease progressionR Q Warren, M T Wong, G P Melcher, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 6, 1994
Type 1/type 2 cytokine modulation of T-cell programmed cell death as a model for human immunodeficiency virus pathogenesisM Clerici, A Sarin, R L Coffman, et al.
Journal of Clinical Microbiology|February 1, 1995
Serologic evaluation of human immunodeficiency virus type 1-infected individuals from Argentina and the United States indicates a similar distribution of subgroup B isolatesR Q Warren, M T Wong, G P Melcher, et al.
The Journal of Infectious Diseases|December 1, 1993
Longitudinal analysis of the humoral immune response to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in rapidly progressing and nonprogressing HIV-1-infected subjectsM T Wong, R Q Warren, S A Anderson, et al.
Annals of Internal Medicine|August 1, 1993
Delayed-type hypersensitivity skin testing predicts progression to AIDS in HIV-infected patientsS P Blatt, C W Hendrix, C A Butzin, et al.
The Journal of Infectious Diseases|July 1, 1995
In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virusM J Dolan, M Clerici, S P Blatt, et al.
The Journal of Infectious Diseases|April 1, 1995
Multivariate models for predicting progression to AIDS and survival in human immunodeficiency virus-infected personsS P Blatt, W F McCarthy, B Bucko-Krasnicka, et al.
Science (New York, N.Y.)|December 10, 1993
Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitroM Clerici, D R Lucey, J A Berzofsky, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|April 3, 1998
Size and duration of zidovudine benefit in 1003 HIV-infected patients: U.S. Army, Navy, and Air Force natural history data. Military Medical Consortium for Applied Retroviral ResearchL I Gardner, S H Harrison, C W Hendrix, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
AIDS (London, England)|April 1, 1995
Rates of p24 antigenemia and viral isolation in comparable white and black HIV-infected subjects. Military Medical Consortium for Applied Retroviral ResearchA E Brown, J R Lane, K F Wagner, et al.
Clinical and Diagnostic Laboratory Immunology|July 1, 1995
Presence of neutralizing antibodies to heterologous human immunodeficiency virus type 1 isolates in sera of infected individuals is not predictive of rate of disease progressionR Q Warren, M T Wong, G P Melcher, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 6, 1994
Type 1/type 2 cytokine modulation of T-cell programmed cell death as a model for human immunodeficiency virus pathogenesisM Clerici, A Sarin, R L Coffman, et al.
Journal of Clinical Microbiology|February 1, 1995
Serologic evaluation of human immunodeficiency virus type 1-infected individuals from Argentina and the United States indicates a similar distribution of subgroup B isolatesR Q Warren, M T Wong, G P Melcher, et al.
The Journal of Infectious Diseases|December 1, 1993
Longitudinal analysis of the humoral immune response to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in rapidly progressing and nonprogressing HIV-1-infected subjectsM T Wong, R Q Warren, S A Anderson, et al.
Annals of Internal Medicine|August 1, 1993
Delayed-type hypersensitivity skin testing predicts progression to AIDS in HIV-infected patientsS P Blatt, C W Hendrix, C A Butzin, et al.
The Journal of Infectious Diseases|July 1, 1995
In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virusM J Dolan, M Clerici, S P Blatt, et al.
The Journal of Infectious Diseases|April 1, 1995
Multivariate models for predicting progression to AIDS and survival in human immunodeficiency virus-infected personsS P Blatt, W F McCarthy, B Bucko-Krasnicka, et al.
Science (New York, N.Y.)|December 10, 1993
Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitroM Clerici, D R Lucey, J A Berzofsky, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|April 3, 1998
Size and duration of zidovudine benefit in 1003 HIV-infected patients: U.S. Army, Navy, and Air Force natural history data. Military Medical Consortium for Applied Retroviral ResearchL I Gardner, S H Harrison, C W Hendrix, et al.
Pageof 3